Glomerular C4d Immunoperoxidase in Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy

Brian J. Nankivell1, Chow H. P’Ng2 and Meena Shingde2

1Department of Renal Medicine, Westmead Hospital, Sydney, New South Wales, Australia; and 2Department of Tissue Pathology and Diagnostic Oncology, Institute of Clinical Pathology and Medical Research, Sydney, New South Wales, Australia

**Introduction:** The diagnosis of late antibody-mediated rejection (AMR) is compromised by frequent absence of C4d in peritubular capillaries (C4dptc), termed “C4d-negative” AMR. We hypothesized that glomerular capillary C4d (C4dglomerular) reflected endothelial interaction with antibody and could improve immunologic classification of transplant glomerulopathy (TG).

**Methods:** We evaluated C4d using immunoperoxidase in 3524 consecutive, kidney transplant biopsies from a single center.

**Results:** C4dglomerular was detected in 16.5% and C4dptc in 9.9% of biopsies. C4dglomerular occurred in 60.3% of TG (n = 174) and was absent in normal glomeruli. Epidemiologic risk factors for C4dglomerular were younger, female, living-donor recipients with early AMR, prior treated rejection, and late presentation using multivariable analysis. Semiquantitative C4dglomerular score correlated with donor specific antibody (DSA) level, C4dptc, microvascular inflammation (MVI), Banff cg scores, renal dysfunction, and proteinuria. Principal component analysis colocalized C4dglomerular with histologic AMR. Multivariable analysis of TG found DSA, C4dptc, and post-transplant time associated with C4dglomerular. Addition of C4dglomerular into Banff chronic AMR schema improved its diagnostic sensitivity for TG (verified by electron microscopy [EM]) from 22.2% to 82.4% and accuracy from 59.6% to 93.9%, compared with Banff 2019 using only C4dptc. Tissue C4dglomerular and chronic AMR diagnosis incorporating C4dglomerular were associated with death-censored allograft failure in TG (P < 0.001), independent of the severity of glomerulopathy and chronic interstitial fibrosis.

**Conclusion:** C4dglomerular is a promising diagnostic biomarker of endothelial interaction with antibody which substantially improved test performance of the Banff schema to correctly classify TG by pathophysiology and prognosticate graft loss. We recommend routine C4d immunoperoxidase to minimize underdiagnosis of late AMR in TG.

**Keywords:** antibody-mediated rejection; Banff schema; kidney transplantation

Late-onset AMR is characterized by de novo DSA from underimmunosuppression, glomerulitis, and/or peritubular capillary (PTC) inflammation (MVI), C4d deposition, and chronic morphologic changes, including transplant TG and multilamination of PTC basement membranes. Activated glomerular capillary endothelial cells expand the subendothelial space with fibrillary and neomembrane material forming “double contours” on silver staining.1–4 The pathologic diagnosis of chronic AMR should be accurate and reliable. Underdiagnosis of AMR in the early Banff schema was highlighted by abnormal endothelial transcript expression (indicating molecular AMR) in “C4d-negative” rejection (using diffuse C4dptc3 threshold) and then misclassified as T cell-mediated rejection.5 Iterative reductions of C4dptc thresholds to “focal” C4d2 (10%–50% for immunofluorescence) and “minimal” C4d1 (1%–9% immunoperoxidase)6,7 and incorporation of MVI8 improved sensitivity and reduced false-negative results; however, histologic AMR without DSA or C4dptc remains diagnostic challenges.9–14 A fundamental weakness for diagnosis of chronic active-AMR (CA-AMR) is over-reliance on C4dptc and MVI lesions because target PTC are lost from humoral injury. Capillary endothelial cells undergo apoptosis and detachment in acute AMR causing collapse and luminal occlusion of interstitial microcirculation,15 which progressively disappears with advancing interstitial fibrosis in chronic rejection.16,17 C4dptc positivity rates are only 49.4% in TG (weighted...
average, 12 studies, \( n = 656 \) biopsies).\(^2\)–4,18–26 \( \text{C4d}_{\text{ptc}} \) most often fluctuates in early subclinical AMR (37.0\%) and is insensitive for prediction of parenchymal disease and graft failure.\(^5\)\(^6\) One practical solution is evaluation of \( \text{C4d}_{\text{glomer}} \), a larger antigenic target for DSA deposition. Cleaved C4b covalently binds to adjacent amino acids and carbohydrate moieties on glomerular endothelial cells and basement membrane collagen, via reactive sulfhydryl groups. Stable C4d remains detectable after proteolytic inactivation as the local “footprint” of classical complement system activation by DSA binding within the glomerular capillaries.\(^3\)\(^4\)

The 2001 Banff AMR diagnostic schema originally specified linear \( \text{C4d}_{\text{ptc}} \),\(^29\) excluding glomeruli because C4d immunofluorescence of normal glomeruli is variably positive in mesangium, occasional capillary loops, and collagen autofluorescence from sclerosed glomeruli.\(^30\) Chromogenic C4d immunohistochemistry staining of formalin-fixed, paraffin-embedded tissue although less sensitive avoids this problem: background \( \text{C4d}_{\text{glomer}} \) is absent in normal glomeruli.\(^1\)\(^2\)\(^4\)\(^5\)\(^6\)\(^7\) In complement-activating native glomerular diseases (including membranous, lupus, and immune-complex glomerulonephritis [GN]), mesangial and glomerular capillary C4d immunoperoxidase of formalin-fixed, paraffin-embedded is used for salvage when immunofluorescence tissue is absent.\(^30\)\(^31\) Several transplant studies reported \( \text{C4d}_{\text{glomer}} \) staining in active AMR and chronic TG using immunoperoxidase\(^1\)\(^2\)\(^3\)\(^4\)\(^5\)\(^6\)\(^7\)–27,32,33\); however, its use as a diagnostic biomarker is not currently accepted. We hypothesized that: (i) \( \text{C4d}_{\text{glomer}} \) represents endothelial interaction with antibody in transplanted kidneys; (ii) the magnitude of \( \text{C4d}_{\text{glomer}} \) immunoperoxidase staining correlates with clinical, immunologic, and pathologic humoral activities; and (iii) incorporation into the Banff chronic AMR schema would improve diagnostic sensitivity and improve etiologic classification of late chronic AMR expressed as TG.

We evaluated \( \text{C4d}_{\text{glomer}} \) in a well-characterized cohort of 3524 consecutive adequate samples from ABO-compatible kidney transplant recipients (where confounding complement-mediated diseases were excluded) to calculate \( \text{C4d}_{\text{glomer}} \) prevalence, epidemiologic risk factors, and correlations with authenticated AMR markers, including circulating DSA, histologic MVI, Banff cg scores, and \( \text{C4d}_{\text{ptc}} \). \( \text{C4d}_{\text{glomer}} \) background staining was absent in all preimplantation donor tissues. The suboptimal diagnostic performance of Banff 2019 CA-AMR definition (using only \( \text{C4d}_{\text{ptc}} \))\(^34\) to diagnose confirmed TG was substantially improved by addition of \( \text{C4d}_{\text{glomer}} \) and better discriminated graft failure.

### METHODS

#### Specific aims

The specific study aims were to:

1. establish population prevalence rates for \( \text{C4d}_{\text{glomer}} \);
2. determine clinical epidemiologic risk factors for \( \text{C4d}_{\text{glomer}} \);
3. correlate \( \text{C4d}_{\text{glomer}} \) scores against circulating DSA, histologic markers of antibody, renal dysfunction, and proteinuria;
4. evaluate the test performance of \( \text{C4d}_{\text{glomer}} \) as a diagnostic biomarker in Banff-defined AMR and confirmed TG;
5. compare the clinical performance of Banff 2019 CA-AMR diagnosis (using \( \text{C4d}_{\text{ptc}} \)) to an enhanced Banff definition with \( \text{C4d}_{\text{glomer}} \) for TG diagnosis within a common reference standard subset (Banff cg\( \geq 1b \) and normal, verified by EM); and
6. evaluate the clinical impact of \( \text{C4d}_{\text{glomer}} \) as a diagnostic biomarker for allograft survival in TG.

#### Study Design

The research design was a retrospective, single-center, observational nested cohort study with prospective data collection. It was investigator-initiated, independent, and undertaken without external funding. Institutional ethics was HREC LNR/12/WMEAD/114. STARD checklist for diagnostic studies is included (Supplementary Table S1). Consecutive, kidney transplant biopsy specimens with sufficient tissue from May 2012 to April 2021 were screened. Indication biopsies for cause, post-treatment verification, and surveillance per protocol (at 0, 1, 3, and 12 months for kidney and additional 3, 5, 7, and 10 years for kidney-pancreas recipients) were included. Nonalloimmune diseases (e.g., diabetic nephropathy, BK virus nephropathy) and conditions that activate the complement (recurrent GN, atypical hemolytic uremic syndrome, thrombotic microangiopathy, and ABO-incompatible transplantation) were excluded.

The principal disease of study interest was TG, defined by light microscopy (LM; Banff cg\( \geq 1 \)) as the archetypical expression of chronic AMR, irrespective of DSA status. A test reference subset of TG (Banff cg\( \geq 1b \)) and DSA-negative normal controls (both verified by EM) was used for diagnostic test comparison and \( \text{C4d}_{\text{glomer}} \) evaluation. Banff cg1a and abnormal endothelial activation or hypertrophy without neomembrane (\( \geq 3 \) capillaries, “cg0e”) were independently verified (BN), analyzed separately as diagnostically indeterminate (Figure 1).
Assessment of C4d-glom Immunopathology and Antibody

Histology was contemporaneously scored by 6 specialized nephropathologists and classified using Banff 2019 AMR schema from original lesion scores.34 All samples were tested for C4d using immunoperoxidase in formalin-fixed, paraffin-embedded tissue. Epitope retrieval of unstained sections used mild cell conditioning medium (Ultra CC1, Ventana systems, Tucson, AZ, incubated 95°C/14°C for 36 minutes), specific C4d antihuman primary antibody (rabbit polyclonal anti-C4d antibody, Cell Marque, CA, 37°C for 40 minutes), and visualized using indirect, biotin-free detection (Ultra DAB, Ventana Benchmark ULTRA), as best practice technical recommendations.35

C4d-glom was defined by linear staining of ≥3 glomerular capillary loops. Mesangial staining was disregarded (present in 3.6%, Figure 2b). The dichotomized C4d-glom interobserver kappa score was excellent at 0.950 (CHP and MS). C4d-glom was semiquantitatively scored as: C4d-glom1, faint and/or segmental pattern of any single glomerulus (≤9% glomeruli, Figure 2d); C4d-glom2, mild-to-strong intensity in 10% to 50% glomeruli (segmental or global pattern, Figure 2c and e); and C4d-glom3, mild-to-strong diffuse staining in most (>50%) glomeruli (Figure 2f). Reference native histology (n = 21) and C4d-glom donor samples (n = 140) were retrospectively verified by a single, blinded pathologist (CHP; Supplementary Table S2a).

Tissue for EM was immediately fixed in modified Karnovsky’s solution at biopsy procurement, postfixed with osmium tetroxide, dehydrated in ascending ethanol series, polymerized in Epon resin, ultrathin sectioned, with digital images of 2 or more glomeruli obtained by transmission EM. Anti-HLA specific IgG DSA used specific class I and/or class II assays (LAB-Screen Single Antigen Bead, Luminex, One Lambda, CA), with positivity defined as median fluorescence intensity (MFI) ≥ 500. HLA class I (A, B, C) and class II (DRB1/3/4/5, DQ α/β) alleles were defined by two-field sequence-based typing (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA) after 2017, replacing single-field molecular HLA typing by sequence-specific oligonucleotides (LABType SSO, One Lambda).

Statistical Analysis

Unpaired Student t test or Wilcoxon rank sum tested parametric and nonparametric nominal data, respectively, and Pearson’s or Spearman’s tests for correlations. Analysis of repeated samples used univariable and multivariable generalized estimating equations (GEEs). Multivariable models were constructed following backward elimination and adjusted for confounding factors. Collinearity diagnostics verified final models. C4d-glom score results were confirmed by ordinal logistic regression analysis as ordered categorical values. Survival analyses used first occurrence of C4d-glom or TG from a single unique kidney (avoiding double-counting repeat samples). Kaplan–Meier actuarial survival (log-rank test) was used for binary predictors and Cox regression for multivariable factors. Time-to-event was calculated from index cases. P values were 2-sided, and probability < 0.05 was considered significant. Data are expressed as mean ± SD, unless stated.

RESULTS

Population Screening and Study Exclusions

From 3990 consecutive biopsies screened, exclusions were as follows: unsatisfactory tissue and/or absent glomeruli (n = 135); ABO-incompatible kidneys (n = 62), (atypical) haemolytic uremic syndrome (n = 31) or thrombotic microangiopathy (n = 3); nonalloimmune
disease and GN ($n = 182$); and unavailable C4d results ($n = 53$); leaving 3524 included samples (mean $3.1 \pm 1.8$ per patient, range 1–13) from 1138 recipients (Figure 1 and Supplementary Table S2b).

Study Population Demographics

The mean ($\pm$SD) age was 47.2 ± 12.7 years, 61.8% male, 7.2% retransplanted, 79.0% received deceased donor kidney, and 31.1% kidney-pancreas transplants. HLA mismatch was 3.9 ± 1.8. Induction was basiliximab in 83.9%, antithymocyte globulin in 8.9%, desensitization in 0.6%, nil in 5.6%, and unknown in 1.0%. Early ($\leq 3$ months) acute interstitial, vascular, and C4d-positive antibody rejection occurred in 19.6%, 4.6%, and 5.4%, respectively; and 16.9% received dialysis for delayed function. Prior rejection episodes before biopsy diagnosis were treated with methylprednisolone in 37.4% and antithymocyte globulin in 8.9% of the cases.

Immunosuppression at biopsy included the following: tacrolimus (92.5%) or cyclosporine (6.6%); azathioprine (6.3%), mycophenolate (87.6%), or leflunomide (3.4%); sirolimus/everolimus (1.3%); and prednisolone in 99.6%. Daily doses were: 7.4 ± 6.4 mg for tacrolimus (trough 8.9 ± 3.7 ng/ml); 207 ± 110 mg for cyclosporine (172 ± 141 ng/ml); 1.81 ± 0.38 g for mycophenolate mofetil; and 14.1 ± 6.1 mg for prednisolone.

Prevalence of Glomerular C4d by Time and Diagnosis

The population prevalence of C4d was 16.5% (583/3524) for C4d$_{glom}$ and 9.9% for C4d$_{ptc}$ (350/35244). When classified by dominant clinicopathologic diagnoses, C4d$_{glom}$ occurred in 25.0% of subclinical rejection, 24.8% acute rejection, 21.2% chronic-active T cell mediated rejection, 74.0% chronic AMR, 15.2% interstitial fibrosis and tubular atrophy, 31.9% for calcineurin inhibitor nephrotoxicity, and 11.3% in normal/minor abnormalities (Figure 3 and detailed Supplementary Table S2b). C4d$_{glom}$ occurred in 54.8% for excluded ABO-incompatible, 32.3% (atypical) haemolytic uremic syndrome, 33.3% thrombotic microangiopathy, 9.1% BK virus allograft nephropathy (including inflammation/rejection), and 34.6% for GN cases. TG occurred in 4.9% (174 of 3524) and positive for C4d$_{glom}$ in 60.3% (105 of 174).
A modest early (<1 month) peak and nadir at 2 to 3 months was followed by progressive and sustained increase in C4d_{glomer} paralleling TG and exceeding C4d_{ptc} prevalence (Fig. 3d and e). C4d_{glomer} positive cases demonstrated DSA (in 58.2%) and TG (in 18.0%), whereas TG had DSA (in 63.4%) and C4d_{glomer} (60.3%; Fig. 3c). Principal component analysis found C4d_{glomer} colocalized with AMR histology including Banff cg, mm, ptc, and C4d_{ptc} (Fig. 3f).

**Epidemiologic and Histologic Predictors of Glomerular C4d**

Tabulated comparisons (Table 1 and Supplementary Tables S2 and S3a, S3b) and univariable binomial GEE (n = 3524 biopsies from 1132 patients) of clinical and demographic factors found that C4d_{glomer} was predicted by younger, female, living donor recipients who experienced early T cell-mediated rejection (OR 1.705, 95% CI 1.349–2.154) or AMR (OR 2.598, 95% CI 1.698–3.974) and prior rejection treatment (pulse corticosteroids or antithymocyte globulin, antithymocyte globulin, Supplementary Table S4a). Multivariable binomial GEE confirmed younger, female, living-donor recipients with early AMR, rejection treatment, and late presentation as independent epidemiologic risks for C4d_{glomer} (Supplementary Table S4c and S5).

Independent histologic determinates of C4d_{glomer} included chronic glomerulopathy (Banff cg and mm) and AMR indicators including DSA, Banff C4d_{ptc} and ptc scores, when adjusted for time using multivariable binomial GEE (Table 2 and Supplementary Table S4d and S5). Glomerulitis lost significance. Multivariable ordinal regression confirmed C4d_{glomer} scores increased with Banff cg, mm, ptc, and C4d_{ptc} scores, (logeMFI) DSA, and later post-transplant time (P < 0.001; Supplementary Table S5).
Glomerular C4d Correlations With Antibody and Histology

Within the study population (n = 3524), C4dglomer score correlated with the following: microvascular antibody markers including Banff ptc (rho = 0.216, P < 0.001), g (rho = 0.180, P < 0.001), and MVI scores (rho = 0.231, P < 0.001); chronic glomerular morphologic changes such as Banff cg (rho = 0.290, P < 0.001) and mm (rho = 0.281, P < 0.001) scores; C4d ptc scores (rho = 0.291, P < 0.001); and immunodominant DSA MFI (r = 0.411, P < 0.001; Figure 4 and Supplementary Table S6). Stronger C4dglomer categories paralleled Banff acute microvascular and total inflammation, chronic antibody and fibrosis scores (Figure 4). Moderate C4dglomer score=2 associated with renal dysfunction and proteinuria (P < 0.001).

The test performance of C4dglomer as an individual biomarker to diagnose AMR was evaluated using multiple acute and chronic Banff definitions (n = 3524 samples). For “definitive” Banff 2019 CA-AMR (all 3 criteria needed), the diagnostic sensitivity of C4dglomer was 69.2% (84.7% specificity) and 72.2% (84.6% specificity) for active AMR. For “suspicous” AMR (at least 2 criteria present), sensitivities were 45.7% to 50.5% (specificity 87.2%–88.5%; Supplementary Table S7). In the EM-verified reference subset, the sensitivity of C4dglomer to detect TG (all Banff cg=1b) was 66.7% (specificity 99.0%), 42.4% for

Table 1. Clinical and demographic differences by C4dglomer

| Category (n) | C4dglomer | Absent | P value |
|-------------|-----------|--------|---------|
| Biopsies (n) | 583       | 2941   |         |
| Post-transplant (mo) | 38.1 ± 62.5 | 14.3 ± 33.0 | <0.001 |
| Indication biopsy, n (%) | 224 (38.4) | 771 (26.2) |         |
| Pretransplant factors: | | | |
| Recipient age (yr) | 44.0 ± 12.9 | 47.9 ± 12.6 | <0.001 |
| Recipient female | 252 (43.2) | 1094 (31.2) | 0.006 |
| Living donor | 150 (25.7) | 592 (21.1) | 0.002 |
| Early clinical events before biopsy time: | | | |
| Delayed function | 71 (12.3) | 523 (17.8) | <0.001 |
| Early acute cellular rejection | 160 (27.7) | 529 (18.0) | <0.001 |
| Early vascular rejection | 34 (5.9) | 129 (4.4) | 0.004 |
| Early humoral rejection | 70 (12.1) | 117 (4.0) | <0.001 |
| Prior i.v. corticosteroids | 309 (53.2) | 1075 (36.6) | <0.001 |
| Prior antithymocyte globulin | 168 (28.9) | 508 (17.3) | <0.001 |
| Selected histopathology and antibody results: | | | |
| DSA (MFI) | 3989 ± 6655 | 948 ± 2504 | <0.001 |
| Banff g score | 0.2 ± 0.5 | 0.06 ± 0.3 | <0.001 |
| Banff ptc score | 0.4 ± 0.7 | 0.08 ± 0.4 | <0.001 |
| Banff cg score | 0.3 ± 0.7 | 0.03 ± 0.2 | <0.001 |
| Banff mm score | 0.4 ± 0.7 | 0.08 ± 0.3 | <0.001 |
| C4dglomer score | 1.4 ± 0.6 | 0 ± 0.0 | <0.001 |
| C4dglomer score | 0.4 ± 0.8 | 0.07 ± 0.3 | <0.001 |

Table 2. Predictors of C4dglomer

| Model 1: Epidemiologic risk factors for C4dglomer
| Predictor | OR | 95% CI | P value |
|-----------|----|--------|---------|
| Months post-transplant | 1.010 | 1.008–1.013 | <0.001 |
| Recipient age (yr) | 0.978 | 0.970–0.987 | <0.001 |
| Living donor | 1.346 | 1.037–1.748 | 0.026 |
| Early (<3 mo) AMR | 1.700 | 1.092–2.646 | 0.019 |
| Pulse corticosteroid treatment | 1.402 | 1.111–1.767 | 0.004 |
| Prior antithymocyte globulin | 1.460 | 1.126–1.895 | 0.004 |

| Model 2: Antibody-mediated histologic determinants of C4dglomer
| Predictor | OR | 95% CI | P value |
|-----------|----|--------|---------|
| C4dglomer score | 2.959 | 2.292–3.819 | <0.001 |
| Banff mm score | 2.147 | 1.633–2.824 | <0.001 |
| Banff cg score | 1.697 | 1.196–2.402 | 0.003 |
| Banff ptc score | 1.477 | 1.181–1.847 | <0.001 |
| Any DSA (MFI >500) | 1.582 | 1.244–2.012 | <0.001 |
| Months post-transplant | 1.006 | 1.003–1.009 | <0.001 |

AMR, antibody mediated rejection; C4dglomer, glomerular capillary C4d; C4dptc, C4d in peritubular capillary; DSA, donor specific antibody; MFI, median fluorescence intensity. Comparison of biopsy samples (n = 3526) stratified by any capillary loop glomerular C4d immunoperoxidase staining (C4dglomer=1). Mean ± SD for continuous data, n (%) for countable results (detailed in Supplementary Table S3).

TG and Glomerular C4d

The population prevalence of TG was 4.9% (diagnosed by LM, 174 of 3524) comprising 109 Banff cg1 (62.7%), 36 cg2 (20.7%), and 29 (16.6%) cg3 cases. TG occurred at 79.9 ± 90.7 months with higher serum creatinine (207 ± 132 μmol/l vs. 168 ± 153 for Banff cg0, P < 0.001) and urinary albumin/creatinine (98.5 ± 167 mg/mmol vs. 17 ± 47, P < 0.001; Supplementary Table S9). Independent epidemiologic predictors of TG were female (P = 0.007), living donor recipients (P < 0.001), with prior pulse corticosteroid treatment (P = 0.010), late presentation and higher DSA (MFI, P < 0.001; Supplementary Table S10) using multivariable binomial GEEM (2371 biopsies from 1038 patients).

In TG (n = 174), C4dglomer occurred in 48.6%, 83.3%, and 75.9% of Banff cg1, cg2, and cg3 cases, respectively. C4dglomer scores correlated with Banff cg (rho = 0.367, P < 0.001), MVI (rho = 0.230, P = 0.002), ptc (rho = 0.200, P = 0.008), g (rho = 0.164, P = 0.031); mm (rho = 0.243, P < 0.001); C4dptc scores (rho = 0.232, P = 0.002); and DSA (log2 MFI, rho = 0.351, P < 0.001). C4dglomer in TG was independently predicted by DSA (P = 0.007) and C4dptc (P = 0.047), when controlled for time using multivariable binomial GEEM (Table 4). Banff cg and mm lost

Kidney International Reports (2022) 7, 1594–1607

1599
significance. Sensitivity analysis demonstrated Banff cg failed to independently predict C4dglom when DSA and C4dptc were included into the multivariable model (Supplementary Table S11).

Determinants of Transplant Glomerular Morphology
Analyses restricted to histologic variables found TG was independently determined by mesangial matrix expansion, glomerulitis, and C4dglom, when chronic fibrosis and vascular changes were controlled by

Table 3. Diagnostic performance of C4dglom biomarker in AMR

| Predictor                      | Prevalence (%; n/N) | Sensitivity, % | Specificity, % |
|--------------------------------|---------------------|----------------|----------------|
| Suspicious active AMR          | 11.32 (339/3524)    | 46.1           | 87.2           |
| Definitive active AMR           | 2.04 (72/3524)      | 72.2           | 84.6           |
| Suspicious CA-AMR               | 12.43 (438/3524)    | 50.5           | 88.3           |
| Definitive CA-AMR               | 2.21 (78/3524)      | 69.2           | 84.7           |
| Total suspicious active and CA-AMR | 14.67 (517/3524) | 45.7           | 88.5           |
| Total definitive active and CA-AMR | 3.43 (121/3524) | 65.3           | 85.2           |

Table 4. Predictors of C4dglom in TG

| Predictor                      | OR      | 95% CI          | P value |
|--------------------------------|---------|-----------------|---------|
| Any DSA (MRI >500)             | 2.809   | 1.328–5.943     | 0.007   |
| Any C4dptc (C4dptc ≥1)         | 2.542   | 1.039–6.219     | 0.047   |
| Months post-transplant          | 1.007   | 1.000–1.013     | 0.003   |

C4dglom, glomerular capillary C4d; C4dptc, C4d in peritubular capillary; DSA, donor specific antibody; MFI, median fluorescence intensity; OR, odds ratio; TG, transplant glomerulopathy.

Summary diagnostic test performances of the C4dglom component to diagnose active and chronic Banff 2019 AMR as “definitive” (all 3 criteria present) or “suspicious” (≥2 diagnostic criteria) defined by light microscopy from the study population (n = 3524), and TG (n = 108) in the reference subset and DSA-negative normal cases (n = 100) all verified by electron microscopy. Key: CA-AMR. AMR prevalence percentage by definition used (disease/subtotal tested, detailed Supplementary Table S7).
multivariable binomial GEE (n = 3524 biopsies, 1106 patients, Table 5 and Supplementary Table S10). C4dptc and ptc lost significance. TG was independently predicted by C4dglom (P < 0.001) in all multivariable histologic models, irrespective of post-transplant time, DSA, glomerulitis, Banff ci and cv. C4dptc lost significance being superseded by C4dglom (Supplementary Table S10). Ordinal regression confirmed Banff cg score increased by C4dglom. Banff mm and ci scores, DSA, and late TG presentation (P = 0.003 to P < 0.001, data not found).

**Table 5. Histologic determinants of TG**

| Determinant | OR     | 95% CI  | P value |
|-------------|--------|---------|---------|
| Banff cg score | 2.929  | 2.219–3.866 | <0.001  |
| C4Dglom score | 2.235  | 1.744–2.866 | <0.001  |
| Banff ci score | 1.417  | 1.125–1.785 | 0.003   |
| Banff cv score | 1.400  | 1.077–1.820 | 0.012   |

C4dglom, glomerular capillary C4d; OR, odds ratio; TG, transplant glomerulopathy. *Post-transplant time could substitute for Banff ci score (detailed Supplementary Table S10). Multivariable predictors of TG defined by light microscopy (Banff cg ≥1, n = 3524 biopsies from 1106 patients) using binomial generalized estimating equation restricted to pathologic independent variables.

Diagnostic Utility of Banff 2019 AMR Criteria for TG

A reference subgroup of proven TG was defined and verified by EM (n = 359 including Banff 1a, DSA prevalence 59.3%) for comparative diagnostic testing. The principal study group of interest was LM-defined, EM-verified TG (Banff cg ≥1b, n = 108), irrespective of DSA status. A normal control group was formed by exclusion of 936 indication biopsies (leaving 2588 protocol), with contemporaneous DSA results (n = 1295), which tested negative (n = 781), with available EM (excluding Banff cg1a, cg0e, and multilamination of PTC≥4, n = 373), with nil acute Banff scores (n = 267), and absent/minimal chronic pathology (allowing only Banff ci ≤1), leaving 100 verified normal controls without AMR or DSA.

In EM-confirmed pathology, C4dglom occurred in 1% of NIL, 20.6% cg0e, 29.3% DSA-negative TG, and 57.3% of DSA-positive TG (Figure 5). In DSA-positive TG, C4dglom occurred in 47.1% Banff cg1a and 77.5% for Banff cg ≥1b, and unrelated to cg score (Figure 5b), and MVI in 26.2% Banff cg1a and 54.7% for Banff cg ≥1b. Cross comparison showed lower C4dptc prevalence relative to C4dglom in all TG subcategories (Figure 5d and e). The test performances of Banff 2019 CA-AMR schema (using C4dptc for criterion 2, endothelial interaction with antibody) to diagnose TG (Banff cg ≥1b, n = 108) irrespective of DSA (detected in 65.7%) were evaluated against normal controls without DSA (n = 100) in the EM-verified reference subset. Mild Banff cg1a (invisible by LM, n = 136) and cg0e minor endothelial changes (n = 388) were excluded as indeterminant diagnoses.

The Banff 2019 CA-AMR criteria demonstrated suboptimal sensitivity of 22.2% to detect TG (accuracy 59.6%, specificity 100%), which primarily failed from infrequent expression of diagnostic lesions including C4dptc (23.1%), glomerulitis (39.8%), PTCs (14.8%), MVI (29.6%, and noncountable with Banff i = 1, 23.1%), and/or DSA (65.7%). In contrast to 23.1% C4dptc prevalence, C4dglom was present in 66.7% of TG, and either biomarker occurred in 70.4%. Expansion of Banff CA-AMR definition to include C4dglom and/or C4dptc, the sensitivity for TG diagnosis increased to 82.4% and accuracy improved to 90.9% (Table 6 and Supplementary Table S12).

Graft failure and Glomerular C4d and CA-AMR Diagnosis

Death-censored graft survival from first TG index biopsy in 134 kidneys (56.7% with C4dglom, 76/134) was followed for 45.5 months (median, interquartile range 22–74). Kaplan–Meier survival was reduced by C4dglom ≥1 (log rank 10.973, P < 0.001, Figure 6a). C4dptc ≥1 (log rank 6.317, P = 0.012), and DSA (log rank 6.826, P = 0.009). TG graft loss also increased with C4dptc (Figure 6d). TG from indication biopsies (n = 73, 105.1 months, C4dglom 65.8%, C4dptc 28.8%) demonstrated accelerated failure and 5-year graft survival of 29.6% with C4dglom (log rank 9.600, P = 0.002; Figure 6e). Sensitivity analysis (all first biopsies with rejection of all phenotypes and normal) from the study population (n = 695 unique kidneys) confirmed C4dglom (17.3% prevalence) was associated with graft loss (log rank 8.160, P = 0.004, Figure 6f).

Univariable predictors of graft loss included younger, living donor recipients, HLA mismatch, later presentation time, and serum creatinine. DSA (hazard ratio [HR] 2.778, 95% CI 1.248–6.181), C4dglom (HR 3.412, 95% CI 1.581–7.366, P = 0.002), C4dptc (HR 2.352, 95% CI 1.182–4.679), Banff ti, ci, ct, cv, cg, and mm scores also predicted graft failure using univariable Cox regression (Supplementary Table S13). Banff PTC was marginal (P = 0.051) and glomerulitis unrelated.

C4dglom was an independent pathologic predictor of graft failure in TG (P = 0.003), along with Banff cg and ci scores using multivariable Cox regression. Presentation time and fibrosis were interchangeable indicators of time-dependent scarring (Table 7 and Supplementary Table S13). DSA and MVI lost significance to C4dptc and/or C4dglom in multivariable models. A mixed clinicopathologic model found independent predictors of graft loss were late presentation in younger recipients with renal dysfunction, severe
glomerulopathy, and interstitial fibrosis (Banff cg and ci scores), with marginal significance for C4d glom and C4d ptc ($P = 0.093$ and $0.097$, respectively).

Graft failure in TG was better determined when diagnosis incorporated C4d glom. TG (Banff fcg $1b$) classified using Banff 2019 CA-AMR diagnostic criteria ($n = 134$, $12.7\%$ with all criteria) had no impact on outcome (log rank HR $1.354$, $95\%$ CI $0.0469$–$3.904$, $P = 0.739$; Figure 6b, Supplementary Table S14). In comparison, diagnosis of CA-AMR definition using C4d ptc and/or C4d glom more accurately predicted graft failure in TG (log rank HR $3.081$, $95\%$ CI $1.603$–$5.922$, $P = 0.002$; Figure 6c).

**DISCUSSION**

The current histologic diagnostic algorithm for Banff chronic AMR is neither accurate nor reliable, with a poor sensitivity to detect TG due to infrequent expression of key diagnostic criteria (C4d ptc, MVI, and DSA). Failure to accurately classify “C4d-negative” AMR (lacking C4d ptc and/or DSA) compromises clinical management. Inclusion of C4d glom (with C4d ptc) into the Banff schema CA-AMR (as criterion 2, endothelial interaction with antibody) dramatically increased the diagnostic sensitivity and accuracy for EM-verified TG.
compared with Banff 2019 definition using only C4d<sub>ptc</sub> and was associated with allograft failure. We consider TG expressing C4d<sub>glom</sub> as prima facie evidence of chronic AMR, irrespective of DSA status.

Our hypothesis that glomerular C4d is a tissue biomarker reflecting circulating antibody was supported by the following: correlations with DSA detection and MFI level; associations with all histologic AMR diagnostic lesions (C4d<sub>ptc</sub>, glomerulitis, MVI, and Banff cg); colocalization of C4d<sub>glom</sub> with AMR pathologic features using principal component analysis; strong independent association of Banff cg score with C4d<sub>glom</sub> using multivariable analyses controlling for confounding variables; biologically plausible epidemiologic predictors (prior AMR and treated rejection); and prognostication of graft failure.

Figure 6. Allograft survival by C4d<sub>glom</sub> and Banff CA-AMR classifiers. (a) Kaplan–Meier death censored graft survival of TG (from first index biopsy) of 134 unique kidney transplants dichotomized by C4d<sub>glom</sub> immunoperoxidase (P < 0.001, vs. C4d<sub>glom</sub>0 TG). (b) Actuarial graft loss of TG indistinguishable by Banff 2019 CA-AMR criteria (using only C4d<sub>ptc</sub>). (c) Actuarial graft loss curves separated using expanded Banff CA-AMR criteria (C4d<sub>ptc</sub> and C4d<sub>glom</sub>) with greater graft loss in TG kidneys (P = 0.002). (d) Graft survival of TG dichotomized by C4d<sub>ptc</sub> (n = 134, P < 0.012 vs. negative C4d<sub>ptc</sub>). (e) Graft survival of TG diagnosed by indication biopsy (73 unique kidney transplants) dichotomized by C4d<sub>glom</sub> (P = 0.002 vs. negative C4d<sub>glom</sub>). (f) Graft survival of the study population (from first index biopsy) of 575 unique kidney transplants dichotomized by C4d<sub>glom</sub> (P < 0.001 vs. negative C4d<sub>glom</sub>), AMR, antibody mediated rejection; C4d<sub>glom</sub>, glomerular capillary C4d; C4d<sub>ptc</sub>, C4d in peritubular capillary; CA-AMR, chronic-active antibody mediated rejection; TG, transplant glomerulopathy.

Table 7. Histologic determinants of graft failure in transplant glomerulopathy

| Determinant     | HR     | 95% CI     | P value |
|-----------------|--------|------------|---------|
| Banff cg score  | 2.932  | 1.777–4.840| <0.001  |
| C4D<sub>glom</sub> score | 1.593 | 1.171–2.168 | 0.003   |
| Banff ci score<sup>a</sup> | 1.993 | 1.282–3.099 | 0.002   |

C4d<sub>glom</sub>, glomerular capillary C4d; C4d<sub>ptc</sub>, C4d in peritubular capillary; DSA, donor specific antibody; HR, hazard ratio; MFI, microvascular inflammation.

<sup>a</sup>Banff ci score could substitute for post-transplant time (detailed Supplementary Table S13).

Parsimonious histologic predictors of death-censored allograft failure in chronic transplant glomerulopathy (first biopsy occurrence in a single unique kidney, n = 134) using multivariable Cox regression model. DSA and MFI lost significance when either C4d<sub>ptc</sub> or C4d<sub>glom</sub> were incorporated into the multivariable model.
C4d<sub>glomerulus</sub> immunoperoxidase is not a new diagnostic lesion but previously reported in acute and chronic rejection involving antibody. Feucht observed abundant diffuse C4d<sub>glomerulus</sub> staining in 46.2% (42/93) and focal/segmental staining in 18.6% (8/43) in early (≤1 months) indication biopsies (n = 93) from sensitized, re-transplanted recipients with high panel-reactive antibodies, followed by accelerated graft loss. A subsequent study of high immunologic risk (regrafted, sensitized, DSA) recipients demonstrated C4d<sub>glomerulus</sub> in 100% of early and late acute cellular rejection (27/27 and 25/25) and all late “chronic rejection” samples (12/12), versus C4d<sub>ptc</sub> in 84.5%, 84.6%, and 83.3%, respectively. Shimizu et al. reported that C4d<sub>glomerulus</sub> in 92% (81% diffuse, 11% focal) of TG (n = 50, mean Banff cg = 1.9, glomerulitis 76%, PTCs 86%) was diagnostically superior to C4d<sub>ptc</sub> (occurring in 57%). Gloor et al. reported that C4d<sub>glomerulus</sub> in 33.3% (9/28) of TG (n = 55, 49% subclinical, cg = 1.8) was more sensitive than C4d<sub>ptc</sub> (17.9%). Sijpkens et al. found C4d<sub>glomerulus</sub> in 90.9% of TG (10/11, cg = 2.3) and 15.3% (2/13) of “chronic allograft nephropathy” cases versus 36.4% for C4d<sub>ptc</sub> (4/11). Batal et al. correlated C4d<sub>glomerulus</sub> (25.3% TG prevalence) with Banff cg score. For acute AMR, Kikic et al. and Valente et al. correlated C4d<sub>glomerulus</sub> with DSA, glomerulitis, C4d<sub>ptc</sub>, and univariable graft loss. Gasim et al. reported C4d<sub>glomerulus</sub> in 66.7% of TG (vs. 26.7% C4d<sub>ptc</sub>, n = 30, cg = 2.6) which correlated with cg score, DSA, and C4d<sub>ptc</sub>. Hence, multiple studies consistently found superior sensitivity for C4d<sub>glomerulus</sub> in TG and chronic (active) AMR compared with C4d<sub>ptc</sub>.

Our study indicated that C4d<sub>glomerulus</sub> is an ideal diagnostic biomarker of antibody in TG, with excellent test sensitivity and accuracy, high prevalence, and superior prognostication of graft failure compared with C4d<sub>ptc</sub>. C4d immunoperoxidase from automated PPFE tissue processing and indirect, biotin-free detection (Ultra DAB, Ventana Benchmark), produced clean and accurate results in thickened glomerular basement membrane segments was often less intense or absent with areas of lamina rara interna expansion (C4d<sub>glomerulus</sub> was 20.6% in cg0e). Our immunoperoxidase study of TG found C4d<sub>glomerulus</sub> was not independently predicted by Banff cg when circulating DSA and C4d<sub>ptc</sub> were controlled by multivariable analysis, indicating C4d<sub>glomerulus</sub> represents a tissue-bound biomarker of antibody “activity” rather than nonspecific glomerular thickening.

The current Banff chronic AMR schema uses 3-tier diagnostic criteria comprising the following: (1) DSA (or C4d<sub>ptc</sub> surrogate); (2) C4d (C4d<sub>ptc</sub>), conditional MVI, and/or expression of validated AMR transcripts/classifiers reflecting endothelial interaction with DSA; and (3) chronic tissue injury as TG and/or multilamination of PTC. Noninclusion of C4d<sub>glomerulus</sub> compromised the diagnostic sensitivity for CA-AMR. Addition of C4d<sub>glomerulus</sub> immunoperoxidase (to C4d<sub>ptc</sub> in criterion 2) improved sensitivity (from 22.2% to 82.4%) and accuracy (from 59.6% to 93.9%) for the diagnosis of TG in a head-to-head comparison within a EM-verified reference set. Specificity was 100%. Gasim reported 54% sensitivity and 84% specificity for C4d<sub>glomerulus</sub> immunoperoxidase for TG (n = 82, including Banff 1a), with strong staining being 100% specific. In comparison, C4d<sub>glomerulus</sub> immunofluorescence was 89% sensitive but less specific at 48%. We recommend reporting “positive” C4d<sub>glomerulus</sub> immunoperoxidase and not mislabelling “C4d negative” AMR simply by absence of C4d<sub>ptc</sub>. Incorporation of C4d<sub>glomerulus</sub> for diagnosis of antibody was supported by good sensitivity and specificity results in acute and chronic AMR Banff diagnoses (by LM) and EM-confirmed TG. C4d<sub>glomerulus</sub> strongly associated with graft failure in all scenarios. The 5-year graft survival of TG in indication biopsies was only 29.6%. We advocate inclusion of C4d<sub>glomerulus</sub> in Banff schema for CA-AMR diagnosis (with caveats for GN,
Clinical Research

C4dglom score standardization, and gene signature are protocols (including biotin-free visualization methods), modern automated technologies utilizing current prognostic histologic markers of AMR, and was associated with graft failure. Incorporation of C4dglom into Banff diagnostic and prognostic biomarker of endothelial capillary loops, and nonspecific sclerosed glomeruli. Further collaborative research using normal controls for background staining, archetypal DSA-positive TG to assess individual laboratory sensitivity, specificity, and reproducibility using modern automated technologies utilizing current protocols (including biotin-free visualization methods). C4dglom score standardization, and gene signature are unmet clinical needs. In summary, C4dglom immunoperoxidase is a promising diagnostic and prognostic biomarker of endothelial interaction with antibody, which correlated with circulating DSA, severity of glomerulopathy, diagnostic histologic markers of AMR, and was associated with graft failure. Incorporation of C4dglom into Banff 2019 chronic AMR schema substantially improved diagnostic sensitivity and test accuracy, reduced immunologic and misclassification of TG cases. We recommend scoring C4dglom in TG and advocate its inclusion into the Banff schema to minimize underdiagnosis of late chronic AMR.

Disclosure

All the authors declared no competing interests.

Acknowledgments

This study was investigator-initiated, independent, and undertaken without external funding.

Data Sharing Statement

Extensive summary data and analysis are presented within the supplemental material which contains 14 highly detailed tables of de-identified summated clinical data with their univariable and multivariable statistical analyses to allow for open scientific scrutiny. Federal privacy laws and local institutional ethics forbid the placement of confidential individual patient information onto any public data-sharing website nor allow for its unauthorized sharing. Specific questions of clinical science may be directed to the corresponding author.

Author Contributions

All authors participated in manuscript review and histologic definitions. CHP was responsible for blinded reference histology and for C4d background, MS for C4d comparisons, and BJN for research design and data analysis.

Supplementary Material

Table S1. STARD guidelines for diagnostic studies: checklist.
Table S2a. Background normal capillary loop glomerular staining.
Table S2b. C4dglom prevalence in transplanted kidneys by dominant diagnosis.
Table S3a. Clinical and demographic differences by glomerular C4d.
Table S3b. Detailed descriptive pathology by glomerular C4d staining.
Table S4a. Univariable clinical predictors of glomerular C4d using GEE.
Table S4b. Univariable histologic determinants of glomerular C4d.
Table S4c. Multivariable epidemiologic risk factors for glomerular C4d.
Table S4d. Multivariable histologic determinants of glomerular C4d.
Table S5. Confirmatory analysis: Antibody-related determinants of C4dglom using ordinal regression against clinical and histologic risk factors.
Table S6. Correlations with glomerular and peritubular capillary C4d.
Table S7. Diagnostic performance of C4dglom against antibody-mediated rejection diagnosed using Banff 2019 criteria in population and TG subset.
Table S8. Diagnostic performance of C4dglom in reference test subset of transplant glomerulopathy verified by electron microscopy (n = 359). Transplant glomerulopathy and relation of Baff cg cases using binomial GEE.
Table S9. Detailed descriptive summary data of transplant glomerulopathy.
Table S10. Predictors of transplant glomerulopathy using GEE (3 models).
Table S11a. Sensitivity analysis I: Univariable predictors of glomerular C4d in transplant glomerulopathy using binomial GEE.
Table S11b. Sensitivity analysis II: Multivariable predictors of C4dglom in transplant glomerulopathy.
Table S12. Ultrastructural verified reference test performance of Banff 2019 AMR diagnostic criteria in transplant glomerulopathy: head-to-head comparison to expanded criteria incorporating C4dglomer.

Table S13a. Univariable determinants of graft failure using Cox regression.

Table S13b. Multivariable predictors of graft failure using Cox regression.

Table S14. Kaplan Meier graft failure in TG by Banff AMR definitions.

REFERENCES

1. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. *Am J Transplant*. 2007;7:2124–2132. https://doi.org/10.1111/j.1600-6143.2007.01895.x

2. Haas M, Mirocha J. Early ultrastructural changes in renal allografts: correlation with antibody-mediated rejection and transplant glomerulopathy. *Am J Transplant*. 2011;11:2123–2131. https://doi.org/10.1111/j.1600-6143.2011.03647.x

3. Shimizu T, Ishida H, Toki D, et al. Clinical and pathological analyses of transplant glomerulopathy cases. *Nephrology (Carlton)*. 2014;19(Suppl 3):21–26. https://doi.org/10.1111/nep.12243

4. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. *Am J Transplant*. 2007;7:1743–1752. https://doi.org/10.1111/j.1600-6143.2007.01838.x

5. Sis B, Jhangri GS, Bunng S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. *Am J Transplant*. 2009;9:2312–2323. https://doi.org/10.1111/j.1600-6143.2009.02761.x

6. Sis B, Mengel M, Haas M, et al. Banff ’09 meeting report. antibody mediated graft deterioration and implementation of Banff working groups. *Am J Transplant*. 2010;10:464–471. https://doi.org/10.1111/j.1600-6143.2009.02987.x

7. Mengel M, Sis B, Haas M, et al. Banff 2011 meeting report. New concepts in antibody-mediated rejection. *Am J Transplant*. 2012;12:563–570. https://doi.org/10.1111/j.1600-6143.2011.03926.x

8. Sis B, Einecke G, Chang J, et al. Cluster analysis of lesions in nonselected kidney transplant biopsies: microcirculation changes, tubulointerstitial inflammation and scarring. *Am J Transplant*. 2010;10:421–430. https://doi.org/10.1111/j.1600-6143.2009.02938.x

9. Callemeyn J, Ameye H, Lerut E, et al. Revisiting the changes in the Banff classification for antibody-mediated rejection after kidney transplantation. *Am J Transplant*. 2021;21:2413–2423. https://doi.org/10.1111/apt.16474

10. Filippone EJ, Farber JL. Histologic antibody-mediated kidney allograft rejection in the absence of donor specific HLA antibodies. *Transplantation*. 2021;105:e181–e190. https://doi.org/10.1097/TP.0000000000003797

11. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA).

12. Orandi BJ, Alachkar N, Kraus ES, et al. Presentation and outcomes of C4d-negative antibody-mediated rejection after kidney transplantation. *Am J Transplant*. 2016;16:213–220. https://doi.org/10.1111/ajt.13434

13. Senev A, Coemans M, Lerut E, et al. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: clinical presentation and implications for outcome. *Am J Transplant*. 2019;19:763–780. https://doi.org/10.1111/ajt.15074

14. Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. *Curr Opin Organ Transplant*. 2010;15:42–48. https://doi.org/10.1097/MOT.0b013e3283592a50

15. Liptak P, Kemeny E, Morvay Z, et al. Peritubular capillary damage in acute humoral rejection: an ultrastructural study on human renal allografts. *Am J Transplant*. 2005;5:2870–2876. https://doi.org/10.1111/j.1600-6143.2005.01102.x

16. Bishop GA, Waugh JA, Landers DV, et al. Microvascular destruction in renal transplant rejection. *Transplantation*. 1989;48:408–414. https://doi.org/10.1097/00007890-198909000-00011

17. Ishii Y, Sawada T, Kubota K, et al. Injury and progressive loss of peritubular capillaries in the development of chronic allograft nephropathy. *Kidney Int*. 2005;67:321–332. https://doi.org/10.1111/j.1523-1755.2005.00085.x

18. Batal I, Girnita A, Zeevi A, et al. Clinical significance of the distribution of C4d deposits in different anatomic compartments of the allograft kidney. *Mod Pathol*. 2008;21:1490–1498. https://doi.org/10.1038/modpathol.2008.152

19. Crary GS, Raissian Y, Gaston RC, et al. Optimal cutoff point for immunoperoxidase detection of C4d in the renal allograft: results from a multicenter study. *Transplantation*. 2010;90:1099–1105. https://doi.org/10.1097/TP.0b013e3181f7fec9

20. De Serres SA, Noel R, Cote I, et al. 2013 Banff criteria for chronic active antibody-mediated rejection: assessment in a real-life setting. *Am J Transplant*. 2016;16:1515–161525. https://doi.org/10.1111/ajt.13624

21. Gasim AH, Chua JS, Wolterbeek R, et al. Glomerular C4d deposits can mark structural capillary wall remodelling in thrombotic microangiopathy and transplant glomerulopathy: C4d beyond active antibody-mediated injury: a retrospective study. *Transpl Int*. 2017;30:519–532. https://doi.org/10.1111/tri.12936

22. Mauvyi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. *J Am Soc Nephrol*. 2001;12:574–582. https://doi.org/10.1681/ASN.V123574

23. Nickelet V, Zeiler M, Guad F, et al. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. *J Am Soc Nephrol*. 2002;13:242–251. https://doi.org/10.1681/ASN.V131242

24. Regele H, Bohmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. *J Am Soc Nephrol*. 2002;13:2371–2380. https://doi.org/10.1097/01.asn.0000025780.03790.0f
25. Sijpkens YW, Joosten SA, Wong MC, et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. *Kidney Int*. 2004;65:2409–2418. https://doi.org/10.1111/j.1523-1755.2004.00662.x

26. Wavamunno MD, O’Connell PJ, Vitalone M, et al. Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies. *Am J Transplant*. 2007;7:2757–2768. https://doi.org/10.1111/j.1600-6143.2007.01995.x

27. Feucht HE. Complement C4d in graft capillaries – the missing link in the recognition of humoral alloreactivity. *Am J Transplant*. 2003;3:646–652. https://doi.org/10.1034/j.1600-6143.2003.00171.x

28. Stegall MD, Chedid MF, Cornell LD. The role of complement in antibody-mediated rejection in kidney transplantation. *Nat Rev Nephrol*. 2012;8:670–678. https://doi.org/10.1038/nrneph.2012.212

29. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. *Am J Transplant*. 2003;3:708–714. https://doi.org/10.1034/j.1600-6143.2003.00072.x

30. Drachenberg CB, Papadimitriou JC, Chandra P, et al. Epidemiology and pathophysiology of glomerular C4d staining in native kidney biopsies. *Kidney Int Rep*. 2019;4:1555–1567. https://doi.org/10.1016/j.ekir.2019.07.015

31. Zwirner J, Felber E, Herzog V, et al. Classical pathway of complement activation in normal and diseased human glomeruli. *Kidney Int*. 1989;36:1069–1077. https://doi.org/10.1038/ki.1989.302

32. Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. *Clin Exp Immunol*. 1991;86:464–470. https://doi.org/10.1111/j.1365-2249.1991.tb02954.x

33. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. *Kidney Int*. 1993;43:1333–1338. https://doi.org/10.1038/ki.1993.187

34. Loupy A, Haas M, Roufosse C, et al. The Banff 2019 kidney meeting [Report;I]: Updates on and clarification of criteria for T cell- and antibody-mediated rejection. *Am J Transplant*. 2020;20:2318–2331. https://doi.org/10.1111/ajt.15898

35. Mengel M, Chan S, Climenhaga J, et al. Banff initiative for quality assurance in transplantation (BIFQUIT): reproducibility of C4d immunohistochemistry in kidney allografts. *Am J Transplant*. 2013;13:1235–1245. https://doi.org/10.1111/ajt.12193

36. Muczynski KA, Ekle DM, Coder DM, Anderson SK. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. *J Am Soc Nephrol*. 2003;14:1336–1348. https://doi.org/10.1097/01.asn.0000061778.08085.9f

37. Kicic Z, Regele H, Nordmeyer V, et al. Significance of peritubular capillary, glomerular, and arteriolar C4d staining patterns in paraffin sections of early kidney transplant biopsies. *Transplantation*. 2011;91:440–446. https://doi.org/10.1097/TP.0b013e3182052be8

38. Valente M, Furian L, Della Barbera M, et al. Glomerular C4d immunoreactivity in acute rejection biopsies of renal transplant patients. *Transplant Proc*. 2012;44:1897–1900. https://doi.org/10.1016/j.transproceed.2012.07.062

39. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. *J Am Soc Nephrol*. 2007;18:1046–1056. https://doi.org/10.1681/ASN.2007010073

40. Nickeleit V, Mengel M, Colvin RB. Renal transplant pathology. In: Jennette JC, D’Agati VD, Olson JL, Silva FG, eds. *Heptinstall’s Pathology of the Kidney*. 7th ed. Wolters Kluwer; 2015:1321–1459.

41. Halloran PF, Venner JM, Madill-Thomsen KS, et al. Review: the transcripts associated with organ allograft rejection. *Am J Transplant*. 2018;18:785–795. https://doi.org/10.1111/ajt.14600